Molecules

Flortaucipir

Target TauClass Small molecule (pyrido-indole)Other names AV-1451, T807

10ongoing trials
1radiolabelled forms
1approved products
834publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C16H10FN3
Molar mass (g/mol)
263.27
Exact mass (Da)
263.0859
XLogP
3.3
H-bond donors
1
H-bond acceptors
3
Rotatable bonds
1
Heavy atoms
20
InChIKey
GETAAWDSFUCLBS-UHFFFAOYSA-N
PubChem record
CID 71059746 ↗
IUPAC name
7-(6-fluoro-3-pyridinyl)-5H-pyrido[4,3-b]indole
SMILES
C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]flortaucipirImaging262.2710Phase 3Tauvid US EU FR

Ongoing trials · 10Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
Tau protein tracersNCT03143374 · Other neurodegenerative diseasesPhase 3RecruitingUniversity of Pennsylvania1
Tau protein tracers2023-505430-10-00 · Alzheimer's disease and cognitive disordersPhase 3RecruitingAmsterdam UMC1
Tau protein tracers2024-519995-20-00 · Alzheimer's disease and cognitive disordersPhase 3Not yet recruitingInstitut National De La Sante Et De La Recherche Medicale1
Tau protein tracersNCT06723015 · Alzheimer's disease and cognitive disordersPhase 2By invitationMayo Clinic1
Tau protein tracers2024-517634-17-01 · Alzheimer's disease and cognitive disordersPhase 2RecruitingAmsterdam UMC Stichting1
Tau protein tracersNCT06297590 · Alzheimer's disease and cognitive disordersPhase 1RecruitingEli Lilly and Company3
HEAD · Tau protein tracersNCT05361382 · Alzheimer's disease and cognitive disordersPhase 1Active, not recruitingTharick Pascoal3
AV1451 ADC · Tau protein tracersNCT03809351 · Alzheimer's disease and cognitive disordersPhase 1RecruitingUniversity of Alabama at Birmingham1
Tau protein tracersNCT07580703 · Alzheimer's disease and cognitive disordersPhase 1RecruitingEli Radiopharma1
Add-Tau · Tau protein tracersNCT02958670 · Alzheimer's disease and cognitive disordersNo phaseActive, not recruitingUniversity of Zurich1
Other trials listing it among the interventions (comparator, associated scan) · 4
Amyloid tracersNCT04263337 · Stroke and traumaPhase 1Active, not recruitingUniversity of North Carolina, Chapel Hill1
Amyloid tracersNCT00950430 · Alzheimer's disease and cognitive disordersNo phaseBy invitationMayo Clinic1
SEED-AD · Amyloid tracersNCT03821857 · Alzheimer's disease and cognitive disordersNo phaseRecruitingMayo Clinic1
Amyloid tracersNCT03582488 · Parkinson's disease and parkinsonian syndromesNo phaseBy invitationKejal Kantarci1

PublicationsAll publications in PubMed ↗

834 publications in PubMed for the query below; the most recent:

flortaucipir[tiab] OR AV-1451[tiab]

  1. Neurofibrillary tangle deposition in primary idiotypic isocortices using flortaucipir PET in histopathologically confirmed Alzheimer's disease iScience, 2026
  2. Tau extent is associated with lower cognition in Down syndrome-related Alzheimer's disease Alzheimers Dement, 2026
  3. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes Alzheimers Dement, 2026
  4. Tau-PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head-to-head comparison of Flortaucipir and MK6240 Alzheimers Dement, 2026
  5. Mid-life candidate vascular plasma biomarkers are associated with MRI markers of vascular brain injury and amyloid- and tau-PET in cognitively healthy adults J Alzheimers Dis, 2026
  6. (18)F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers Ann Nucl Med, 2026
  7. Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II Eur J Nucl Med Mol Imaging, 2026
  8. Utility of Amyloid Beta and Tau Positron Emission Tomography Scans for Identifying Early-Stage Neurodegenerative Changes in Former Professional Football Players and Healthy Controls: Results from the Brain Health Initiative J Neurotrauma, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Flortaucipir. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/flortaucipir/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.